CORT Stock Forecast 2025-2026
Distance to CORT Price Targets
CORT Price Momentum
🤔 Considering Corcept (CORT)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest CORT Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, CORT has a bullish consensus with a median price target of $96.50 (ranging from $76.00 to $130.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $56.01, the median forecast implies a 72.3% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Nash at Canaccord Genuity, projecting a 132.1% upside. Conversely, the most conservative target is provided by Joon Lee at Truist Securities, suggesting a 35.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CORT Analyst Ratings
CORT Price Target Range
Latest CORT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CORT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $115.00 |
| Feb 27, 2025 | Piper Sandler | David Amsellem | Overweight | Maintains | $78.00 |
| Feb 11, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $115.00 |
| Feb 7, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $80.00 |
| Jan 30, 2025 | Canaccord Genuity | Edward Nash | Buy | Maintains | $130.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $80.00 |
| Oct 18, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $80.00 |
| Sep 30, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $76.00 |
| Sep 18, 2024 | Piper Sandler | David Amsellem | Overweight | Maintains | $67.00 |
| Jul 31, 2024 | Canaccord Genuity | Edward Nash | Buy | Maintains | $78.00 |
| Jul 30, 2024 | Piper Sandler | David Amsellem | Overweight | Maintains | $38.00 |
| Jul 30, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $45.00 |
| Jul 30, 2024 | Canaccord Genuity | Edward Nash | Buy | Maintains | $38.00 |
| Jul 1, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $35.00 |
| Jun 17, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $65.00 |
| Jun 4, 2024 | Truist Securities | Joon Lee | Buy | Reiterates | $65.00 |
| May 29, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $40.00 |
| May 2, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $40.00 |
| May 2, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $44.00 |
| Apr 23, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $38.00 |
Corcept Therapeutics Inc. (CORT) Competitors
The following stocks are similar to Corcept based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Corcept Therapeutics Inc. (CORT) Financial Data
Corcept Therapeutics Inc. has a market capitalization of $5.89B with a P/E ratio of 45.4x. The company generates $675.04M in trailing twelve-month revenue with a 20.9% profit margin.
Revenue growth is +34.3% quarter-over-quarter, while maintaining an operating margin of +13.9% and return on equity of +23.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Corcept Therapeutics Inc. (CORT) Business Model
About Corcept Therapeutics Inc.
Pharmaceutical company developing cortisol-modulating drugs.
Corcept Therapeutics generates revenue by developing and marketing FDA-approved drugs that target severe endocrine disorders, particularly Cushing's syndrome, as well as psychiatric and metabolic diseases. Their business model is centered on leveraging research and development to expand their product portfolio and address unmet medical needs in the healthcare sector.
Founded in 1998 and based in Menlo Park, California, Corcept Therapeutics is committed to advancing medical science through innovative therapeutic approaches. The company focuses on understanding cortisol's role in various health conditions, which enhances its position within the pharmaceutical and biotechnology industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
500
CEO
Dr. Joseph K. Belanoff M.D.
Country
United States
IPO Year
2004
Website
www.corcept.comCorcept Therapeutics Inc. (CORT) Latest News & Analysis
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors in Corcept Therapeutics (NASDAQ:CORT). Affected investors can find more information at bgandg.com/CORT.
The investigation into Corcept Therapeutics may indicate potential legal issues or financial irregularities, impacting investor confidence and stock performance.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors who purchased Corcept Therapeutics (NASDAQ:CORT) securities. More info is available at bgandg.com/CORT.
The investigation into Corcept Therapeutics may indicate potential legal or financial issues, which could impact stock performance and investor sentiment.
Pomerantz LLP is investigating claims for investors of Corcept Therapeutics (CORT). Affected investors should contact Danielle Peyton for more information.
The investigation into Corcept Therapeutics may indicate potential legal issues or financial misconduct, which could impact stock performance and investor confidence.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors who purchased Corcept Therapeutics (NASDAQ:CORT) securities. More information is available on their website.
The investigation into Corcept Therapeutics may signal potential legal or financial issues, impacting investor confidence and stock performance.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Corcept Therapeutics (NASDAQ:CORT). Interested parties can find more information at bgandg.com/CORT.
The investigation into Corcept Therapeutics could indicate legal issues or potential financial risks, affecting stock performance and investor sentiment.
Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM trial to investigate endogenous hypercortisolism in patients with resistant hypertension.
Corcept's MOMENTUM trial could expand its market potential by addressing a significant condition, potentially boosting revenue and stock performance if successful.
Frequently Asked Questions About CORT Stock
What is Corcept Therapeutics Inc.'s (CORT) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Corcept Therapeutics Inc. (CORT) has a median price target of $96.50. The highest price target is $130.00 and the lowest is $76.00.
Is CORT stock a good investment in 2025?
According to current analyst ratings, CORT has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $56.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CORT stock?
Wall Street analysts predict CORT stock could reach $96.50 in the next 12 months. This represents a 72.3% increase from the current price of $56.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Corcept Therapeutics Inc.'s business model?
Corcept Therapeutics generates revenue by developing and marketing FDA-approved drugs that target severe endocrine disorders, particularly Cushing's syndrome, as well as psychiatric and metabolic diseases. Their business model is centered on leveraging research and development to expand their product portfolio and address unmet medical needs in the healthcare sector.
What is the highest forecasted price for CORT Corcept Therapeutics Inc.?
The highest price target for CORT is $130.00 from Edward Nash at Canaccord Genuity, which represents a 132.1% increase from the current price of $56.01.
What is the lowest forecasted price for CORT Corcept Therapeutics Inc.?
The lowest price target for CORT is $76.00 from Joon Lee at Truist Securities, which represents a 35.7% increase from the current price of $56.01.
What is the overall CORT consensus from analysts for Corcept Therapeutics Inc.?
The overall analyst consensus for CORT is bullish. Out of 9 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $96.50.
How accurate are CORT stock price projections?
Stock price projections, including those for Corcept Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
